To mitigate the severe toxicity of promising pan-RAS inhibitors, companies are adopting antibody-drug conjugate (ADC) technology. This marks a strategic expansion for ADCs, moving beyond traditional cytotoxic chemotherapy payloads to delivering highly specific targeted therapies, aiming to improve the therapeutic window of potent new drug classes.
Recent findings from the AACR conference show a trend away from discovering new T-cell function-promoting targets. Instead, researchers are focusing on novel targets that alter the tumor microenvironment, such as breaking down collagen or repolarizing immune cells, to make existing therapies like checkpoint inhibitors more effective.
The scarcity of new melanoma targets at the AACR conference doesn't indicate a solved problem. Instead, it reflects a strategic shift in the field. Researchers are prioritizing innovation in modalities (e.g., mRNA vaccines) and combinations with established PD-1 inhibitors to enhance efficacy, rather than focusing on discovering novel biological pathways.
The current M&A wave is unique because it includes both public and private company takeouts. This creates a robust capital recycling engine, providing quick returns to VCs (from private sales) and public specialist funds (from public takeouts). This capital is then immediately redeployed into new early and later-stage companies, sustaining the innovation ecosystem.
Kurma Partners' recent fundraise highlights a key challenge: while specialist and corporate investors eagerly back early-stage biotech, generalist institutional LPs are shifting away. These generalists now demand shorter hold times and favor funds investing in clinical-stage companies closer to an exit, creating a potential funding squeeze for preclinical innovation.
Elvara Medicines is developing a CDK4/6 inhibitor, a class known for treating breast cancer, for rheumatoid arthritis. This innovative approach targets synoviocytes, non-immune cells responsible for joint damage. This provides a mechanism that is orthogonal to traditional immune-focused RA therapies like TNF inhibitors, potentially creating a new treatment paradigm.